Zymeworks
Zymeworks Announces Leadership Appointments and Transitions on January 12, 2026
Zymeworks; leadership appointments; board changes; Brian Cherry; Mark Hollywood; Sabeen Mekan; corporate strategy
Jazz and Zymeworks’ Ziihera Achieves Practice-Changing Results in Phase 3 Trial for First-Line HER2-Positive Gastroesophageal Adenocarcinoma
Ziihera; zanidatamab; Jazz Pharmaceuticals; Zymeworks; HER2; gastroesophageal adenocarcinoma; HERIZON-GEA-01; stomach cancer
Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer
Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing
Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study
Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation
Zymeworks Halts Development of ZW171 T-cell Engager After Phase 1 Trial Assesses Benefit-Risk Profile
Zymeworks; ZW171; T-cell engager; mesothelin; cancer; clinical trial; drug development; benefit-risk profile; dose-limiting toxicity